• Je něco špatně v tomto záznamu ?

Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study

G. Corby, NL. Barclay, EH. Tan, E. Burn, A. Delmestri, T. Duarte-Salles, A. Golozar, WY. Man, I. Tietzova, D. Prieto-Alhambra, D. Newby

. 2024 ; 13 (9) : 2187-2201. [pub] 20240921

Status neindexováno Jazyk angličtina Země Čína

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002447

BACKGROUND: Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases. METHODS: We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method. RESULTS: Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males. CONCLUSIONS: The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002447
003      
CZ-PrNML
005      
20250123101931.0
007      
ta
008      
250117s2024 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/tlcr-24-241 $2 doi
035    __
$a (PubMed)39430337
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Corby, George $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
245    10
$a Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study / $c G. Corby, NL. Barclay, EH. Tan, E. Burn, A. Delmestri, T. Duarte-Salles, A. Golozar, WY. Man, I. Tietzova, D. Prieto-Alhambra, D. Newby
520    9_
$a BACKGROUND: Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases. METHODS: We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method. RESULTS: Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males. CONCLUSIONS: The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Barclay, Nicola L $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Tan, Eng Hooi $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Burn, Edward $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Delmestri, Antonella $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Duarte-Salles, Talita $u Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain $u Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Golozar, Asieh $u Odysseus Data Services, Cambridge, MA, USA $u OHDSI Center at the Roux Institute, Northeastern University, Boston, MA, USA
700    1_
$a Man, Wai Yi $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Tietzova, Ilona $u First Department of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Prieto-Alhambra, Daniel $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK $u Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/0000000239506346
700    1_
$a Newby, Danielle $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK
773    0_
$w MED00186389 $t Translational lung cancer research $x 2218-6751 $g Roč. 13, č. 9 (2024), s. 2187-2201
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39430337 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101925 $b ABA008
999    __
$a ok $b bmc $g 2254579 $s 1238450
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 9 $d 2187-2201 $e 20240921 $i 2218-6751 $m Translational lung cancer research $n Transl Lung Cancer Res $x MED00186389
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...